Skip to main content

RVMD Revolution Medicines, Inc.

Healthcare

191.31 Close 10/30
Since 2024-12-02 +269.3%
Open
188.38
High
192.75
Low
187.28
Prev close
190.27
Volume
1.1M
Amplitude
2.87%
P/B
15.7
Revenue YoY (TTM)
-100.0%
52W 56.66 224.31

Is Revolution Medicines, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Good, Risk / liquidity: Good; Valuation: Expensive, Quality: Weak.

Valuation Expensive Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -21.59 N/A
Price / book 15.73 95th percentile Expensive
Free-cash-flow yield (%) -3.87 34th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak ROE, TTM is Lagging.
ROE, TTM (%) -67.85 14th percentile Lagging
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Diluted EPS growth, TTM YoY is Top, but Revenue growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) -100 3th percentile Lagging
Diluted EPS growth, TTM YoY (%) 96.45 84th percentile Top
Momentum Good 240-day return is Top; 60-day return is Good.
60-day return (%) -3.29 59th percentile Good
240-day return (%) 182.38 99th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 369,054,042 96th percentile Top
60-day annualized volatility (%) 39.85 46th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Revolution Medicines, Inc. (RVMD) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Revolution Medicines, Inc. to every stock like it

AI finds several complementary traits of Revolution Medicines, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Revolution Medicines, Inc.

Revolution Medicines, Inc. (RVMD) peers and tracking

Watchlist

This page refreshes daily after the close. Add Revolution Medicines, Inc. to your watchlist to track signal changes on your next visit.

Revolution Medicines, Inc. (RVMD) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 87.44%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
15 historical occurrences (since 2020-09-30)

Average forward return after Top-quintile 6-month momentum

20-day: Win 57.1%, Sample 14, Median +2.28%, Excess -0.13%, Beat mkt rate 64.3%

60-day: Win 35.7%, Sample 14, Median -6.57%, Excess -6.31%, Beat mkt rate 28.6%

120-day: Win 64.3%, Sample 14, Median +4.68%, Excess +0.09%, Beat mkt rate 42.9%

120 days after: historical avg +9.81%

20-day +1.5%
60-day -1.42%
120-day +9.81%
20-day
60-day
120-day
Win
57.1%
35.7%
64.3%
Sample
14
14
14
Median
+2.28%
-6.57%
+4.68%
Excess
-0.13%
-6.31%
+0.09%
Beat mkt rate
64.3%
28.6%
42.9%

Over 14 occurrences, 120-day forward avg gained 9.81%, beat the market by 0.09 pts; win rate 64.3%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 times historically; 60-day forward avg +5.96%, win rate 61.5%, beating the market by +2.7 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.